Have a personal or library account? Click to login
Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach Cover

Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach

Open Access
|Apr 2025

Figures & Tables

Figure 1.

2D interaction plots of (a) berberine, (b) curcumin, (c) resveratrol, (d) silymarin, (e) tocopherol, (f) ginger, (g) ginseng, (h) danshen, (i) anthocyanin, and (j) pirfenidone with TGF-β protein. TGF-β, transforming growth factor-beta.
2D interaction plots of (a) berberine, (b) curcumin, (c) resveratrol, (d) silymarin, (e) tocopherol, (f) ginger, (g) ginseng, (h) danshen, (i) anthocyanin, and (j) pirfenidone with TGF-β protein. TGF-β, transforming growth factor-beta.

Figure 2.

2D interaction plots of (a) berberine, (b) curcumin, (c) resveratrol, (d) silymarin, (e) tocopherol, (f) ginger, (g) ginseng, (h) danshen, (i) anthocyanin, and (j) pirfenidone with TNF-α. TNF-α, tumor necrosis factor-alpha.
2D interaction plots of (a) berberine, (b) curcumin, (c) resveratrol, (d) silymarin, (e) tocopherol, (f) ginger, (g) ginseng, (h) danshen, (i) anthocyanin, and (j) pirfenidone with TNF-α. TNF-α, tumor necrosis factor-alpha.

The results of in silico docking study for different ligands with TNF-α

ProteinLigandNo. of hydrogen bondsInteraction energy (kcal/mol)Inhibition coefficient (μm)Prominent bonds
TNF-αBerberine0–7.116.11Pi sigma, pi alkyl
Curcumin3–7.175.54Hydrogen bond, Pi sigma, Pi T shaped
Resveratrol4–5.8849.02Hydrogen bond, Pi anion
Silymarin5–7.215.17Hydrogen bond, Pi sigma, Pi stacked
Tocopherol1–5.9841.16Hydrogen bond, Pi sigma, pi alkyl
Ginger3–3.910.011Hydrogen bond, pi alkyl
Ginseng3–8.500.590Hydrogen bond, pi alkyl
Danshen2–7.215.22Hydrogen bond, pi alkyl
Anthocyanin1–7.413.72Hydrogen bond, Pi donor hydrogen bond, pi sigma, pi alkyl
Pirfenidone1–6.3322.81Hydrogen bond, pi sigma, pi alkyl

The different etiologies of chronic liver disease in the context of fibrogenesis

PathogenesisStudy implications
Viral hepatitis (Hepatitis B and C)Viral hepatitis is a major cause of chronic liver inflammation and fibrosis. The hepatitis viruses directly infect hepatocytes, leading to immune-mediated liver damage, chronic inflammation, and subsequent fibrogenesis. TGF-β is known to play a crucial role in the fibrogenic response to viral infection by promoting the activation of HSCs and ECM deposition.In the context of viral hepatitis, the inhibition of TGF-β by the herbal compounds identified in our study (e.g., danshen and ginseng) could be particularly beneficial in reducing fibrosis progression. TNF-α inhibition might also help mitigate the chronic inflammatory response triggered by viral infection, thus potentially slowing down the fibrogenic process [3537].
ALDChronic alcohol consumption leads to liver injury through oxidative stress, lipid peroxidation, and the production of pro-inflammatory cytokines, including TNF-α. Alcoholinduced activation of HSCs and the resulting ECM deposition are key contributors to fibrosis in ALD. The role of TGF-β in promoting fibrogenesis is also prominent in ALD.The compounds that target TNF-α, such as ginseng, may help reduce inflammation and hepatocyte apoptosis associated with ALD [38]. Additionally, targeting TGF-β could be effective in mitigating the progression of fibrosis in ALD by reducing HSC activation and ECM accumulation [39].
NAFLD and NASHNAFLD and NASH are increasingly recognized as leading causes of liver fibrosis. The pathogenesis involves insulin resistance, lipid accumulation in hepatocytes, oxidative stress, and chronic inflammation. TGF-β plays a pivotal role in driving fibrosis in NASH by inducing the transformation of HSCs into myofibroblasts. TNF-α also contributes to inflammation and hepatocyte injury in NAFLD/NASH.The findings suggest that the herbal compounds with strong TGF-β inhibitory effects, such as danshen, may be particularly effective in treating fibrosis in NAFLD/NASH [40]. Additionally, TNF-α inhibition by compounds like silymarin could help alleviate inflammation and slow down the progression to fibrosis [41].
AIHAIH is characterized by immune-mediated attack on hepatocytes, leading to chronic inflammation and fibrosis. The persistent activation of immune cells and the production of cytokines, including TNF-α, are central to the pathogenesis of AIH. TGF-β is also involved in the fibrotic response in AIH.Herbal compounds that inhibit TNF-α and TGF-β may offer therapeutic benefits in AIH by reducing immune-mediated inflammation and subsequent fibrosis. The dual inhibition of these pathways could potentially slow the progression of fibrosis and improve liver function in patients with AIH [42, 43].

The results of in silico docking study for different ligands with TGF-β

ProteinLigandNo. of hydrogen bondsInteraction energy (kcal/mol)Inhibition coefficient (μm)Prominent bonds
TGF-βBerberine0–8.210.953Pi cation, pi sigma, pi alkyl
Curcumin0–6.0636.41Pi cation, pi sigma, pi alkyl
Resveratrol4–8.660.447Hydrogen bond, Amide pi stacked
Silymarin4–8.091.18Hydrogen bond, Pi cation
Tocopherol1–8.410.689Hydrogen bond, pi alkyl
Ginger0–5.4699.52Pi sigma, pi alkyl
Ginseng2–10.830.011Hydrogen bond, pi alkyl
Danshen2–11.580.003Hydrogen bond, Pi cation, pi anion, pi sigma, pi alkyl
Anthocyanin0–8.730.396Pi donor hydrogen bond, Pi-sulfur, Pi lone pair, amide pi stacked
Pirfenidone0–7.037.08Pi cation, pi sigma, pi sulfur, pi alkyl
DOI: https://doi.org/10.2478/abm-2025-0010 | Journal eISSN: 1875-855X | Journal ISSN: 1905-7415
Language: English
Page range: 78 - 85
Published on: Apr 30, 2025
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year

© 2025 Tanya Ralli, Abdulsalam Alhalmi, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.